Ajay Nirula

6.8k total citations · 2 hit papers
51 papers, 2.1k citations indexed

About

Ajay Nirula is a scholar working on Immunology, Dermatology and Infectious Diseases. According to data from OpenAlex, Ajay Nirula has authored 51 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Immunology, 12 papers in Dermatology and 11 papers in Infectious Diseases. Recurrent topics in Ajay Nirula's work include Psoriasis: Treatment and Pathogenesis (15 papers), Dermatology and Skin Diseases (11 papers) and SARS-CoV-2 and COVID-19 Research (9 papers). Ajay Nirula is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (15 papers), Dermatology and Skin Diseases (11 papers) and SARS-CoV-2 and COVID-19 Research (9 papers). Ajay Nirula collaborates with scholars based in United States, Canada and United Kingdom. Ajay Nirula's co-authors include Paul Klekotka, Susan L. Kalled, Scott Glaser, Greg Kricorian, Jesse Roth, Kim Papp, Alan R. Shuldiner, Ngozi Erondu, Maria Greenwald and Mark C. Genovese and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Ajay Nirula

50 papers receiving 2.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

2016 376 citations Kim Papp, Kristian Reich et al. profile →
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis

2023 74 citations Jay Tuttle, Edit Drescher et al. New England Journal of Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ajay Nirula	1.2k	521	509	354	277	51	2.1k
Steven J. Padula	1.7k 1.4×	439 0.8×	504 1.0×	546 1.5×	255 0.9×	44	2.9k
Nicholas J. Wilson	2.1k 1.7×	415 0.8×	299 0.6×	537 1.5×	278 1.0×	37	2.9k
Manuela Capone	1.7k 1.4×	176 0.3×	190 0.4×	282 0.8×	266 1.0×	45	2.4k
Ute Laggner	925 0.7×	380 0.7×	151 0.3×	239 0.7×	233 0.8×	15	1.6k
Sinisa Savic	1.3k 1.0×	240 0.5×	649 1.3×	1.3k 3.8×	173 0.6×	142	3.1k
Maria Teresa Fiorillo	1.2k 1.0×	152 0.3×	891 1.8×	405 1.1×	104 0.4×	82	2.5k
Kieron Leslie	805 0.6×	514 1.0×	405 0.8×	1.2k 3.4×	100 0.4×	57	2.2k
Ming-Hong Xie	2.1k 1.7×	338 0.6×	199 0.4×	709 2.0×	227 0.8×	31	3.3k
Shin‐ichiro Kagami	2.0k 1.6×	264 0.5×	407 0.8×	261 0.7×	870 3.1×	56	2.9k
Furen Zhang	445 0.4×	369 0.7×	262 0.5×	213 0.6×	120 0.4×	118	1.5k

Countries citing papers authored by Ajay Nirula

Since Specialization

Citations

This map shows the geographic impact of Ajay Nirula's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ajay Nirula with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ajay Nirula more than expected).

Fields of papers citing papers by Ajay Nirula

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ajay Nirula. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ajay Nirula. The network helps show where Ajay Nirula may publish in the future.

Co-authorship network of co-authors of Ajay Nirula

This figure shows the co-authorship network connecting the top 25 collaborators of Ajay Nirula. A scholar is included among the top collaborators of Ajay Nirula based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ajay Nirula. Ajay Nirula is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Metz, Peter, Howard Bregman, Rishi G. Vaswani, et al.. (2025). Highly Selective and Reversible STAT6 Inhibition Demonstrates Potential for Differentiated Efficacy and Safety Profile in Type 2 Allergic Inflammation. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A1319–A1319. 2 indexed citations

Forman, Seth, Dipak Patel, Alexa B. Kimball, et al.. (2025). A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa. Journal of the American Academy of Dermatology. 94(2). 530–538.

Köester, Anja, Derrick R. Witcher, Mark Lee, et al.. (2025). Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study. Nature Communications. 16(1). 4082–4082. 1 indexed citations

Silverberg, Jonathan I., David Rosmarin, Raj Chovatiya, et al.. (2024). The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nature Communications. 15(1). 9230–9230. 12 indexed citations

Patel, Dipak, Martin Böhm, Himanshu P. Upadhyaya, et al.. (2024). Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19. Infectious Diseases and Therapy. 13(10). 2123–2134. 2 indexed citations

Tuttle, Jay, Edit Drescher, Jesus Abraham Simón Campos, et al.. (2023). POS0307 A PHASE 2 TRIAL OF PERESOLIMAB FOR ADULTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 82. 397–397. 1 indexed citations

Benschop, Robert J., Jay Tuttle, Lin Zhang, et al.. (2022). The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. Science Translational Medicine. 14(655). eabn3041–eabn3041. 20 indexed citations

Dougan, Marcelle, Ajay Nirula, Robert Gottlieb, et al.. (2021). Bamlanivimab+etesevimab for treatment of COVID-19 in high-risk ambulatory patients. 29(1). 33–33. 6 indexed citations

Cohen, Max, Ajay Nirula, Mary Marovich, et al.. (2021). Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting. 29(1). 32–33. 4 indexed citations

10.

Tomalin, Lewis E., Chris B. Russell, Sandra Garcet, et al.. (2019). Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis. Journal of Allergy and Clinical Immunology. 145(3). 922–932. 47 indexed citations

11.

Peyrin‐Biroulet, Laurent, Stephen J. Demarest, & Ajay Nirula. (2018). Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies. Autoimmunity Reviews. 18(2). 123–128. 38 indexed citations

12.

Viswanathan, Hema N., Alex Mutebi, Cassandra E. Milmont, et al.. (2017). Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value in Health. 20(8). 1174–1179. 6 indexed citations

13.

Strober, Bruce, Kim Papp, Mark Lebwohl, et al.. (2016). Clinical meaningfulness of complete skin clearance in psoriasis. Journal of the American Academy of Dermatology. 75(1). 77–82.e7. 93 indexed citations

14.

Mease, Philip J., Mark C. Genovese, Maria Greenwald, et al.. (2014). Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis. New England Journal of Medicine. 370(24). 2295–2306. 308 indexed citations

15.

Biénkowska, Jadwiga, Norm Allaire, Jaya Goyal, et al.. (2014). Lymphotoxin-LIGHT Pathway Regulates the Interferon Signature in Rheumatoid Arthritis. PLoS ONE. 9(11). e112545–e112545. 42 indexed citations

16.

Karanam, Bindhu V., Maria Madeira, Scott A. Bradley, et al.. (2007). Absorption, Metabolism, and Excretion of [14C]MK-0524, a Prostaglandin D2 Receptor Antagonist, in Humans. Drug Metabolism and Disposition. 35(7). 1196–1202. 24 indexed citations

17.

Nirula, Ajay, Mary Ho, Hyewon Phee, Jeroen P. Roose, & Arthur Weiss. (2006). Phosphoinositide-dependent kinase 1 targets protein kinase A in a pathway that regulates interleukin 4. The Journal of Experimental Medicine. 203(7). 1733–1744. 37 indexed citations

18.

Andres, Pietro G., Ajay Nirula, Larry Kane, et al.. (2004). Distinct regions in the CD28 cytoplasmic domain are required for T helper type 2 differentiation. Nature Immunology. 5(4). 435–442. 55 indexed citations

19.

Li, Ching, Aldons J. Lusis, Robert S. Sparkes, Ajay Nirula, & Richard B. Gaynor. (1992). Characterization and chromosomal mapping of the gene encoding the cellular DNA binding protein ILF. Genomics. 13(3). 665–671. 30 indexed citations

20.

Shuldiner, Alan R., Ajay Nirula, Laurie Scott, & Jesse Roth. (1990). Evidence that Xenopus laevis contains two different nonallelic insulin-like growth factor-I genes. Biochemical and Biophysical Research Communications. 166(1). 223–230. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact